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Abstract
Standard statistical models for analyzing inter-individual variability in clinical phar-
macokinetics (non-linear mixed effects; hierarchical Bayesian) require individual data.
However, for environmental or occupational toxicants only aggregated data are usually
available, so toxicokinetic analyses typically ignore population variability. We propose
a hierarchical Bayesian approach to estimate inter-individual variability from the ob-
served mean and variance at each time point, using a bivariate normal (or lognormal)
approximation to their joint likelihood. Through analysis of both simulated data and
real toxicokinetic data from 1,3-butadiene exposures, we conclude that given informa-
tion on the form of the individual-level model, useful information on inter-individual
variability may be obtainable from aggregated data, but that additional sensitivity and
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1 INTRODUCTION
Population analyses of toxicokinetic data are designed to characterize inter-individual
variability in the parameters or predictions of models describing the absorption, distribu-
tion, metabolism, and excretion of toxicants in the body. While such analyses are standard
in pharmaceutical research (Sheiner, Rosenberg, and Melmon 1972; Sheiner 1984; Radine-
Poon 1985; Yuh et al. 1994; Wakefield, Smith, Racine-Poon, and Gelfand 1994; Wakefield
1996; FDA 1999), it has only been since the work of Bois et al. (1996a, b) and Gelman, Bois,
and Jiang (1996) that similar methods have been applied in environmental health sciences.
However, there is only a handful of published population toxicokinetic analyses (recent ex-
amples include Hack, Chiu, Zhao, and Clewell 2006; Marino et al. 2006; Yokley et al. 2006;
and Covington et al. 2007). Population analysis methods such as non-linear mixed effects
or hierarchical Bayesian modeling require individual-level data. However, individual data
from toxicokinetic studies (commonly performed in laboratory animals, but also sometimes
in humans) are often unavailable due to the common practice of summarizing data in the
form of average and SD (which are sufficient for some classical analyses).
Toxicokinetic analyses of older, often under-exploited, datasets therefore typically ignore
population variability because models are fit using reported means and standard errors from
multiple individuals, with those parameters interpreted as representing an “average individ-
ual.” The increasing use of physiologically-based toxicokinetic (PBTK) models, which have
many more parameters than classical pharmacokinetic models, has led to the additional prac-
tice of fixing “known” physiological variables and estimating the remaining chemical-specific
parameters either from in vitro measurements or by “fitting” to aggregated data. There are
several problems with such practices. First, except for the simplest models, the concept of
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“average” parameters is difficult to interpret because of the non-linear relationships between
model parameteres and predictions. Moreover, the general presumption that population
variability can be ignored in laboratory animal experiments because they are performed on
groups of in-bread, genetically similar strains is questionable. Such data still may show a
fairly wide range of kinetic response, especially evident in experiments that report single
data points for individual animals (e.g., Prout, Provan, and Green 1985). Furthermore,
there is typically a large amount of both uncertainty and variability in parameters in PBTK
models that are treated as “known,” and the selection of which parameters to fix and which
to fit is difficult, especially when combining information from various sources and multiple
datasets. Therefore, the practice of fitting to aggregate data in this setting can at the very
least underestimate overall uncertainty and may lead to inaccurate and biased estimates
(Racine-Poon and Smith 1990; Sheiner 1984; Sheiner and Ludden 1992; Woodruff and Bois
1993).
We demonstrate here that population inferences may still be made from aggregated data
if both the observed mean and variance at each time point are available and there is a priori
information about the model and variance structures. In particular, we propose that the
usual hierarchical Bayesian approach, briefly reviewed in Section 2, be extended by treating
individual data as missing (or latent) and marginalizing over it. As described in Section 3, we
approximate the corresponding (generally intractable) joint likelihood of the observed means
and variances with a multivariate normal (or lognormal) distribution having the correct first
and second-order moments. The form of the likelihood depends in part on the underlying
measurement model for the individual data and the assumed variance structure. We derive
approximations based on normal, proportional, and lognormal errors and a single level of
inter-individual variability, which are commonly used in toxicokinetic models. In Section
4, we present comparisons of analyses based on individual data using the full population
approach to analyses based on aggregated data using our proposed approximations for three
simulated data sets and one published human toxicokinetic dataset of controlled exposures
to 1,3-butadiene. We find in our examples that the aggregated analyses provide posterior
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predictions quite similar to individual analyses, albeit with greater posterior uncertainty, as
should be expected. In Section 5, we discuss our conclusion that substantial information on
inter-individual variability may remain in the aggregated data, and that such information
can be recovered through appropriate analyses. Given that some information is still lost
in data aggregation, we suggest that posterior analyses, including checking of model fit,
sensitivity, and parameter identifiability, are of great importance to increasing confidence in
conclusions drawn from analyses of aggregated data.
2 POPULATION MODELING OF
TOXICOKINETICS
As described in Gelman et al. (1996), population modeling of toxicokinetics involves set-
ting up a model in several stages. A nonlinear toxicokinetic model, with predictions denoted
f , describes the absorption, distribution, metabolism, and excretion of a compound and its
metabolites in the body. This model depends on several, usually known, parameters such
as measurement times t, exposure E, and measured covariates φ. Each subject i in a popu-
lation has a set of unknown parameters θi. A population model describes their distribution
in the population, and incorporates existing scientific knowledge about them through prior
distributions on the population mean µ and variance Σ2. Finally, a “measurement error”
model describes deviations ǫ (with variance σ2) between the data y and model predictions
f . This level of the hierarchical model typically also encompasses intraindividual variability
as well as model misspecification, but for notational convenience we refer to it here as “mea-
surement error.” All these components are illustrated graphically in the left part of Figure
1.
***Figure 1 about here.
The posterior distribution for the unknown parameters is obtained in the usual man-
ner by multiplying (A) the prior distribution for the population mean and variance and
the “measurement” error P (µ,Σ2|I)P (σ2|I), (B) the population distribution for the indi-
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vidual parameters P (θ|µ,Σ2, I), and (C) the likelihood P (y|θ, σ2, I), where for notational
convenience, we collapse the knowledge of f , φ, E, t, and n into prior information I:
P (θ, µ,Σ2, σ2|y, I) ∝ P (µ,Σ2|I)P (σ2|I)P (θ|µ,Σ2, I)P (y|θ, σ2, I) (1)
Here, each individual’s parameters θi have the same sampling distribution (i.e., they are iid),
so their joint prior distribution is
P (θ|µ,Σ2, I) =
n∏
i=1
P (θi|µ,Σ2, I). (2)
We consider three different measurement models for the likelihood function, normal errors
(Model I), proportional errors (Model II), and lognormal errors (Model III), as shown in
Table 1. Note that Models II and III are heteroscedastic, a common concern for toxicokinetic
data. Different types of measurements j = 1 . . .m may have different errors, but errors are
otherwise assumed to be iid. Since the individuals are treated as independent given θ1...n,
the total likelihood function is simply







P (yijk|θi, σ2j , tjk) (3)
where n is the number of individuals and m is the number of different types of measurements,
Nj is the number of measurements of type j, and tjk are the times at which measurements
of type j were made. Note we have assumed that the individuals each have the same
experimental design, as would be expected if data were to be aggregated.
3 ANALYSIS OF AGGREGATED DATA
If individual data have been aggregated, and one only has the number of individuals n
and the sample mean mjk and variance s
2
jk of individual measurements at time-point k, then
one must modify the statistical model used. The individual data yijk are considered missing
or latent, and therefore treated as parameters rather than data in a Bayesian context. Thus,
the standard data model becomes part of the population model, and a new data model for
m and s2 is needed. One therefore has a posterior distribution given by
P (θ, σ2, µ,Σ2, y|m, s2, I) ∝ P (θ|µ,Σ2, I)P (µ,Σ2|I)P (σ2|I)P (y|θ, σ2, I)P (m, s2|y, I). (4)
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The additional term P (m, s2|y, I) is formally a δ-function (or 0-1 indicator) specifying the
arithmetic relationship between the observed values yijk and their mean mjk and variance
s2jk. This full statistical model is illustrated in the middle of Figure 1. A possible treatment
of the problem would be to consider the yijk as latent variables and sample (i.e., impute)
them as the other estimands, through Monte Carlo techniques, for example. The logical
relationship between yijk and (mjk, s
2
jk) would complicate such a treatment for continuous
measures (see Marjoram, Militor, Plagnol, and Tavere´ 2003 for discussion of such methods).
The approach we take is to marginalize over the individual measured values yijk, which here
may be considered nuisance parameters, prior to sampling via Monte Carlo. The posterior
distribution we are aiming for, then, has the form
P (θ, σ2, µ,Σ2|m, s2, I) ∝ P (θ|µ,Σ2, I)P (µ,Σ2|I)P (σ2|I)P (m, s2|θ, σ2, I), (5)
with











j |y1jk . . . ynjk)
∏
i
P (yijk|θi, σ2j , I)dyijk (7)
This marginalization is illustrated graphically on the right part of Figure 1. Because the
likelihood function P (mjk, s
2
j |θ, σ2j , I) is conditional on θ, it is independent of the popula-
tion model for inter-individual variability and only depends on the “measurement” model.
Below, we present approximations to P (m, s2|θ, σ2, I) for the different measurement models
considered above. Note that from here on we generally suppress the indices j, k for clarity,
and concentrate on approximations for the integral in equation (7).
3.1 Likelihood Functions for Various Measurement Models
Our general approach is to approximate (for fixed observation type j and time-point tk) the
joint distribution of m and s2 (m and m2 ≡ (m2 + s2) for Model III), conditional on {θi}
(i = 1 . . . n), with a bivariate normal (lognormal for Model III) distribution by matching
the first and second order moments. In particular, we require that the distributions match
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in terms of E[m], E[m2] − E[m]2, E[s2], E[s4] − E[s2]2, and E[ms2] − E[m]E[s2], where E
is the expectation conditional on the values of {θi}. The results of these calculations are
summarized in Table 1.
Table 1 about here.
The moment matching derivations for Models I and II are straight-forward, though te-
dious (and available as supplementary material online). Note that in both cases, the marginal
distributions for the observed mean m are exactly normal, as they are weighted sums of nor-
mal deviates. The covariance between m and s2 is zero for Model I, and non-zero for Model
II.
The derivation for lognormal errors, Model III, merits additional discussion. In this
case, the mean, given by m = (1/n)
∑
fi exp(ǫi), has no simple closed form solution for
its distribution (see Barakat 1976 and Leipnik 1991 for series approaches to calculating the
characteristic function). Several approaches may be taken to approximate it. For large n
and/or small σ2, the central limit theorem can be invoked to approximate the distribution
for m by a normal distribution. For many applications, however, n is quite small (∼ 4), and
Barakat (1976) shows that the coefficient of skewness of the sum distribution decays only
as ∼ n−1/2. Moreover, m and
√
s2 are often of the same order, so it may be important to
incorporate the fact that m must be positive. For these reasons, in many telecommunications
and engineering applications, the sum of lognormal deviates is commonly approximated by
a lognormal distribution by matching moments (e.g., Fenton 1960). Simulations appear to
indicate that this approximation is useful for values up to σ2 ∼ 1 (Fenton 1960; Schwartz
and Yeh 1982), and we adopt this approximation here.
So as to enable use of the same approach, we take as our second “observed” value not
the variance s2 but the second moment m2 ≡ (1/n) ∑ f2i exp(2ǫi) = s2 + m2, as it is also
a sum of lognormal deviates. Thus, we also approximate its distribution by a lognormal
distribution by matching moments, noting that it is the same form as m with σ2 → 4σ2 and
fi → f2i . From the work cited above, this means that the lognormal approximation for m2
is only useful for 4σ2 ≤ 1. Therefore, in general the approximate likelihood for (m,m2) is
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only accurate if σ ≤ 0.5.
The final step, then, is to define the correlation coefficient r of the bivariate lognormal
distribution. We use the same approach as for Models I and II, matching the product moment
E[mm2] (equivalent to matching the central moment because we have already matched E[m]
and E[m2]). We have investigated this approximation in a limited number of simulations for
values of n ≤ 10 and values of σ ≤ 0.5, and have found it to be acceptable as long as the fi has
a relatively small coefficient of variation. If fi are too widely dispersed (e.g., VAR[ln f ] > 1),
then the above formula can sometimes give a value of r > 1. In this case, however, we have
found that using the above formula, but taking σ → 0 (i.e., the limit in which measurement
error is negligible relative to inter-individual variability), so that r → E[f3]/
√
E[f2]E[f4],
gives reasonable results. We take the minimum value of r from the above two formulae as
the one we use in our distribution for m and m2, as shown in Table 1. We find that this
approach sometimes slightly underestimates r by up to a few percent, but ensures that r ≤ 1.
This constraint on r should be checked in posterior simulations.
3.2 Additional Issues for Consideration
3.2.1 Sufficiency and Identifiability
For most non-linear models, there will undoubtedly be some loss of information in data aggre-
gation, so there may be concerns about whether there is still sufficient information to ensure
parameter identifiability in the toxicokinetic and population models. However, even with
individual data, a toxicokinetic model may not be fully identifiable (e.g., the estimation of
decay times of a mixture of exponentials is ill-conditioned, Acton 1970), so this problem is not
unique to aggregated data. At the very least, some a priori information on the system being
analyzed should exist to motivate the formulation of the model and, preferably, informative
prior distributions for its parameters. For instance, in their analysis of tetrachloroethylene
toxicokinetics, Gelman et al. (1996) remarked that both the physiological model and prior
distributions were necessary to ensure identifiability. At best, data from other experiments
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where data were not aggregated could be used to establish the appropriate model form. In
toxicokinetics, if one’s goal is to characterize population variability, then one presumably
already has sufficient information to justify the structure of the individual-level model. So
we focus in particular on parameter identifiability rather than model discrimination.
For non-linear models, these issues are necessarily case-specific, and it may not be possi-
ble to know whether parameter identifiability is a problem prior to performing an analysis.
However, posterior and sensitivity analyses can be done to check that the population pa-
rameters are identifiable given the data. The first evidence for non-sufficiency would be if
the priors and posterior distributions are identical. If the posteriors are narrower, then the
data add some information. A scalar measure τ of the “overlap” between marginal prior and
posterior distributions was proposed by Garrett and Zeger (2000) for latent class models,
and is adapted here for more general use. In particular, for a parameter θ, data y, and prior
information I, prior distribution P (θ|I), and posterior distribution P (θ|y, I), the “overlap
diagnostic” is defined as
τ =
∫
min {P (θ|I), P (θ|y, I)} dθ. (8)
Values of τ near unity (i.e., 100% overlap) indicate weak identifiability from the data, whereas
lower values (Garrett and Zeger 2000 proposed 0.35 as a heuristic threshold) indicated strong
identifiability from the data.
Additionally, it can be determined whether parameters are uniquely identifiable. For
example, in the case of a model yi(t) = (αi + βi)t + ǫit, the parameters αi and βi (and
their corresponding population mean and variance) are not uniquely identifiable without
informative priors, whether one has individual data or aggregated data. If one does not have
informative priors, then this can be detected a posteriori by examining sensitivity of the
results to different diffuse priors, and more directly through examining correlations in the
posterior samples. While visual inspection of the posterior correlation matrix can be useful
in simple cases such as this, in more realistic applications in which more than two parameters
may be involved simultaneously, principal component analysis (PCA) should be a useful tool.
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In particular, performing PCA on the posterior samples, and then comparing the posterior
distributions of the principal components with their priors (i.e., applying the same centering,
scaling, and rotation to samples from their joint prior distribution) should identify any non-
diagonal components which are not identifiable. This should also be applicable to cases such
as yi(t) = θi +ǫit, where variance contributions from different levels of the hierarchical model
are indistinguishable after data aggregation.
3.2.2 Choice of Measurement Model
In standard population analyses, the choice of measurement model is influenced only by
the underlying hypothesis for how the individual data deviate from model predictions. In
our case, how the data are aggregated also plays a role. For most toxicokinetic data, a
lognormal measurement model has been traditionally assumed for individual data points.
One could thus either use Model I by transforming y → ln y, or use Model III. A priori,
Model I would be preferable because it is simpler. However, one could only use this model if
the aggregation was done on the transformed data — e.g., the reported values are geometric
mean and standard deviation. Typically, it is the arithmetic mean and standard deviation
that are reported, so that model III would be the most appropriate. Unfortunately, model
III is also the least robust of the models because of the requirement for σ2 ≤ 0.5 and the
possible lack of stability of the derived correlation coefficient. Model II then is a more robust
alternative approximation that still allows for errors to be proportional to the measured value.
On a practical matter, data are probably most useful in a regime where proportional normal
errors (Model II) and lognormal errors (Model III) are not easily distinguishable. Moreover,
the measurement model also encompasses model misspecification, and a value of σ > 0.5
(i.e., a > 50% error) may be reason to rethink the model.
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3.2.3 Model Checking and Model Choice
As with standard population analyses, model checking is important here. In addition to the
identifiability checks described above, the most basic check is whether the model is consistent
with the data. In the standard population analysis, a typical method to perform this check is
to compare simulated (replicated) data yi,rep with the observed data yi,obs (Gelman, Carlin,
Stern, and Rubin 2003, chap. 6). Analyses of aggregated data are no different except that
the quantities being compared are (m, s2)rep and (m, s
2)obs, as in the examples we give below.
One important limitation of aggregated analyses, however, is that the structural assump-
tions in the population model P (θ|µΣ2) and the measurement model P (y|θ, σ2), which are
not easy to check with individual data, are even more difficult to validate with only ag-
gregated data. Typical techniques for assessing these assumptions include both posterior
simulations as well as sensitivity analyses. For aggregated analyses, posterior simulation is
of somewhat limited usefulness when checking structural assumptions because of the addi-
tional layer of latency. Sensitivity analyses take on greater importance. We illustrate this
below by considering all three measurement models in our analyses.
On the related issue of model choice, there are a large number of statistical methods
for model selection in both a frequentist (e.g., log-likelihood ratio test, Akaike information
criterion) and Bayesian context (e.g., Bayes factors, Bayesian information criterion). These
methods may be less reliable with only aggregated data. Fortunately, the formulation of
toxicokinetic models is motivated primarily by a priori biological and chemical information
rather than statistical measures.
In checking and choosing models, it is also important to make a distinction between the
“statistical” and “practical” significance of model errors. That is, because models such as
those used in toxicokinetics can never be thought of as strictly “true,” statistical lack of fit
may or may not have an impact on the substantive inferences for which the model is used.
Thus, the use of the model should be kept in mind when assessing either the consistency
between model predictions and data or the impact of different model assumptions.
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4 APPLICATION TO DATA ON 1,3-BUTADIENE
We first performed a number of simulations with a simple model and simulated data,
as summarized in Table 2. These simulations covered all three measurement models. We
generated simulated data and compared full population analysis of the individual data with
analyses of the same data aggregated. Computations were performed using WinBUGS ver-
sion 1.4 and MCSim (Version 5.0.0, Bois, Maszle, Revzan, Tillier, and Yuan 2005). In each
case, the results of the analysis of aggregated data were quite consistent with the results of
the full population analysis as well as with the underlying “true” values from which the data
were generated. This offered support for the accuracy of the approach developed here.
***Table 2 about here.
4.1 Butadiene data and model
We then applied our aggregation model to actual toxicokinetic data. The data and model
are described in detail in Bois, Smith, Gelman, Chang, and Smith (1999), and are sum-
marized briefly here. Eight human volunteers were recruited and tested at National Cheng
Kung University in Taiwan. The tests were conducted, under informed consent, with an
Institutional Review Board-approved human subjects protocol. They were exposed to an
ambient concentration Cin(t) of five ppm of 1,3-butadiene for two hours and then zero there-
after. This exposure was the minimum that could be precisely measured, and was well below
Taiwan’s allowable occupational exposure of 10 ppm per eight hour work day for a work-
ing lifetime. For each individual, measurements of body weight (BDW ), minute-ventilation
rate Kin, and blood-air partition coefficients Pba were made along with exhaled breath mea-
surements Cex(tk) at a series of times tk from the beginning of exposure to about one hour
post-exposure. The full dataset for Cex(tk) is displayed in all three panels of Figure 2.
***Figure 2 about here.
The toxicokinetic model was a standard two-compartment model, with a central (volume
Vc) and peripheral compartment (volume Vp) governed by the following differential equations
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for the amount of 1,3-butadiene in each respective compartment Qc(t) and Qp(t):


















where, in addition to the parameters defined above, Pca is the central-to-air partition co-
efficient (assumed to be the measured blood-air partition coefficient Pba); Kcp is the rate
constant for distribution from central to peripheral compartments; Ppc is the peripheral to
central partition coefficient; and Kmet is the metabolic rate constant. The measurement of
covariates BDW , Kin, and Pba greatly improves parameter identifiability in this model.





where a physiological dead space of 30% is assumed. Because the product PpcVp is not
separable, it is treated as a single parameter to ensure identifiability. In addition, the central
volume and the minute-volume are assumed to follow the scaling relations
Vc = sc Vc BDW (12)
Kin = sc Kin BDW
0.7, (13)
so the sc Vc and sc Kin are the actual parameters in the model. Finally, one of the important
uses of the model is the prediction of the amount metabolized AMET, which is given by
AMET =
∫
KmetQc(t) dt. The characterization of the uncertainty and variability in dose
metrics such as this is important for making inferences about the population distribution of
risks from exposure.
In the population model, all the individual-level parameters are assumed to be lognor-
mally distributed with geometric mean exp(µ) and log-variance parameter Σ2. Two modifi-
cations from the Bois et al. (1999) full population analysis were made to allow comparison
between analyses of individual and aggregated data. First, population body weight param-
eters were estimated as part of the model. The population model was lognormal, but the
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likelihood function was assumed to be normal with a measurement standard deviation of
0.25 kg. Second, only time points for which measurements were available in all 8 individuals
were included. Although it is possible to include the missing data points in the model, it
adds a level of complexity that obscures the point of this comparison, which is to compare
full population analysis with an analysis using only aggregated data.
To summarize, each individual i has seven parameters θi = (sc Vc, Kcp, PpcVp, Kmet, Pca,
sc Kin, BDW )i and four types of observations yi = (Pba,obs, Kin,obs, Cex,obs(tk), BDWobs)i.
All errors were assumed lognormal except for BDW , for which errors were assumed to be
normal:
Pba,obs = Pca exp(ǫPca) (14)
Kin,obs = Kin exp(ǫKin) (15)
Cex,obs(tk) = Cex(tk) exp(ǫCex) (16)
BDWobs = BDW + ǫBDW (17)
where in the middle two cases, the model predictions are given by equations (13) and (11),
respectively, and ǫPca ∼ N(0, log 1.17), ǫKin ∼ N(0, log 1.02), ǫCex ∼ N(0, logGSDex), and
ǫBDW ∼ N(0, 0.25 kg) (the first two were based on replicate samples).
Data aggregation was performed using log-transformed measurements (thus using Error
Model I) as well as un-transformed measurements (thus using Error Models II and III), the
last of which are also shown in the left panel of Figure 2. Simulations for all cases were
performed using the MCSim software. To ensure consistency, the original MCSim code used
in Bois et al. (1999) was obtained and modified only where needed.
Prior distributions were the same as in Bois et al. (1999), except for the body weight
parameters, which are new. The prior mean body weight was assigned a uniform distribution
with min and max equal to the min and max measured body weight. The prior variance was
assigned the inverse Gamma distribution with shape parameter of unity and scale parameter
corresponding to a 20% coefficient of variation. All priors are listed in Table 3. As was
done in Bois et al. (1999), 50,000 iterations performed for two independent chains in each
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case. The first 10,000 iterations were discarded, and only every 10 iterations were stored
for analysis. Convergence was monitored through the method of Gelman and Rubin (1992),
and potential scale reduction factors were ≤ 1.03 in the case of individual data, and ≤ 1.01
in the aggregated data cases.
4.2 Comparisons between full population and aggregated analyses
***Figure 3 and Table 3 about here.
Table 3 and Figure 3 summarize the statistical results for both full population and ag-
gregated analyses. There is substantial agreement between the different analyses, as shown
visually in Figure 3. Posterior estimates of all population parameters substantially overlap
for all parameters except for the “measurement” error, which is signficantly larger in the
aggregated analyses (discussed below). While difficult to see in the Figure due to the loga-
rithmic scale, estimates of the population mean parameters (µ), summarized in Table 3, are
not greatly affected by the use of aggregated data, both in terms location and scale. In most
cases, the population variances (expressed as geometric standard deviations exp Σ in Table
3) are only slightly affected as well, with 95% confidence intervals substantially overlapping
among the four analyses. The uncertainties in the population variance parameters exp Σ,
however, are consistently greater in the aggregated analyses. Because the inverse-Gamma
priors on the population variances Σ2 have shape parameter of unity, they have infinite dis-
persion. Thus, greater posterior uncertainty generally leads to higher central estimates and
upper confidence limits. This is reflected in the results, particularly for parameters sc Vc
and sc Kin. It is clear that in these cases, some information was lost in the aggregation
process. The parameter for “measurement” error GSDex was slightly greater in the aggre-
gated analyses. Bois et al. (1999) reported that the analytical errors were estimated to be
about 7%, so this increased “measurement” error reflects additional model error (e.g., due
to the approximations necessary to derive the likelihood functions) and/or intraindividual
variability. Table 3 also shows the posterior uncertainty in the population variability in the
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dose metric AMET for the 8 individuals. The posterior predictions were very similar among
the full population and aggregated analyses, although as with the population parameters,
the uncertainty from the aggregated analyses is slightly greater. Overall, the results of the
population analysis based on aggregated data, using the statistical models developed above,
are consistent (albeit with greater overall uncertainty) with those based on individual data.
4.3 Parameter identifiability
Checks for non-identifiability were conducted on the full population analysis as well as each
aggregated analysis, concentrating on the 15 population parameters (mean and variance for
each of the 7 model parameters, plus residual “measurement” variance). Given the narrowing
of all of these distributions from prior to posterior, one would not expect any parameters to be
completely unidentifiable. Indeed, for population means, values for the overlap diagnostic
τ were ≤ 0.2 except for the metabolic rate constant Kmet (τ ∼ 0.5) and the mean body
weight (τ ∼ 0.6). Moreover, the difference between τ in individual and aggregated analyses
was ≤ 0.05, indicating little information loss for estimated population means. Population
variances were not as well identified, with τ ≥ 0.4. In addition, the differences between
individual and aggregated analyses were greater. The largest changes in overlap were in the
estimated variances of Vc (τ = 0.55 for the individual analysis and τ = 0.83 − 0.90 for the
aggregated analyses) and Ppc (τ = 0.46 for the individual analysis and τ = 0.61−0.64 for the
aggregated analyses). For the other variance parameters, the overlap diagnostic τ changed
by ∼ 0.1.
Further checks examined whether some parameter combinations are only weakly con-
strained by the data. As a visual check, the correlation matrix was calculated with mean
parameters log-transformed (this is more “natural” since the population model and most
of the likelihoods are lognormal) and variability parameters transformed, if necessary, to
variances (e.g., GSD → (lnGSD)2). All non-diagonal correlation coefficients for the popu-
lation parameters were in the interval (-0.4,0.6); of the 15× 14/2 = 105 unique non-diagonal
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elements, only 8 were outside the interval [-0.2,0.2]. Thus, there were some correlations, but
none were extremely strong.
PCA was performed on the posteriors with the R statistical package, with centering
to zero mean and scaling to unit variance (i.e., equivalent to determining the eigenvectors
of the correlation matrix). Each analysis (full population and the three aggregated) had
a slightly different rotation matrix, as should be expected for a non-linear model and the
approximate likelihood functions used. Priors for each set of principal components were
then generated by applying the same transformations to random samples from the joint
prior distribution. All prior principal component [2.5%,97.5%] confidence intervals included
zero (which, by definition, is the posterior mean of the principal components), so there is
no conflict between priors and posteriors even after transformation. Moreover, the posterior
confidence intervals were wholly contained within the prior confidence intervals, with the
prior intervals substantially wider (i.e., by at least 5.9-fold). Thus, we conclude that there
are no substantial parameter identifiability problems.
4.4 Checking Model Fit
Inspection of Figure 2 (middle and right panel) of the scatter in the data points relative
to the scatter of the predictions suggests that full population and aggregated analyses give
similar inter-individual variance in their predictions. Additional checks using the full pos-
terior distribution of predictions for the measured mean and variance for the exhaled air
concentration Cex showed good qualitative consistency between the model predictions and
the underlying (aggregated) data (not shown). However, the scatter during the period of
exposure (t = 0−120 minutes) appears underestimated, perhaps due to intraindividual vari-
ability, which here was not modeled separately but lumped with “measurement” error. This
feature also appears in the full population analysis, as can be seen in the middle panel of
Figure 2. We also note that, for Model III, the posterior range of the “measurement” error
variance σ < 0.5, as required by our approximation for the likelihood function. In addition,
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for Model III, we checked the approximation for the correlation parameter r, and found that
in no case did the moment-matching formula give r > 1, so the σ → 0 approximation was
never used.
Sensitivity analysis is illustrated through comparison of the results from different error
models. Summary statistics are quite similar, with the exception of the variance of sc Vc,
which had greater uncertainty in Model II. In particular, the posterior estimates for the dose
metric AMET were remarkably consistent. Furthermore, graphs of the posterior distributions
as well as the comparisons between data and model predictions showed little sensitivity to
different error models (not shown).
Finally, we note that checks for parameter identifiability (§4.3), model fit and sensitivity
analyses are not unique to the analysis of aggregated data. They could (and should, in
our opinion) be more widely applied to standard population analyses as well. For instance,
parameter identifiability is usually not checked in any formal manner. Model fit is typically
checked only through scatter plots of data and a single posterior prediction (e.g., using a
“random sample” or using population mean parameters), as is shown in Figure 2. As reported
above, we performed additional checks using the full posterior distribution. Checking of the
assumed “measurement” error model, as was done here as part of the sensitivity analyses, is
rarely done.
5 DISCUSSION
Through the use of some conceptually simple approximations, we have developed like-
lihood functions for the observed sample mean and variance of individual measurements,
given a hierarchical population model. Our results illustrate that individual data, while
preferable, are not necessarily essential to analyze population variability in a hierarchical
Bayesian framework. In the cases we analyzed, the resulting posterior distributions between
analysis of individual and aggregated data are very similar. This may not be too surprising
with very simple normal models. Yet, we have found in our examples that the mean and
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variance are nearly sufficient even with a nonlinear model. However, it is important to check
model fit, sensitivity to the likelihood approximation used, and parameter identifiability. For
this last check, we propose principal component analysis as a broadly applicable method.
We have not yet applied our approach to more complex (e.g., PBTK) models, but results
from the butadiene example are encouraging.
There are several important limitations to our approach, some of which are fundamental
and some more practical. First of all, in the examples we have examined, the assumption
has been made (by design for the simulated data and checked in the case of the butadiene
analysis) that other sources of variability (intraindividual variability, measurement error,
model uncertainty, for example) are small compared to inter-individual variability. If this
assumption were not true, the analysis may not be able to disentangle inter- and intra-
individual variability. However, this can be checked a posteriori with the identifiability
checks described above. In addition, structural assumptions, which are not easy to test
even with individual data, are even more difficult to check with aggregated data, so use of
aggregated data for statistical model discrimination is not recommended. Fortunately, for
toxicokinetic models there is usually a priori information on model formulation. Finally,
one should always consider evaluations of the performance of aggregated analyses in the
context of what the data are to be used for, as a mild loss of information or parameter
non-identifiability may not necessarily have a significant impact on posterior inferences of
interest. In our example with 1,3-butadiene, the predicted mean and variance for the dose
metric AMET differed very little among the different analysis, even though some information
on population variability was lost.
On a practical level, the analysis of aggregated data is more computationally burdensome
than if individual data were available. This is due to the more complicated likelihoods, par-
ticularly for Models II and III where there is covariance, and possibly slower convergence.
For instance, on an Intel Pentium 4 2.8 GHz processor running Windows XP with 512 MB
of RAM, two chains of length 50,000 run in MCSim took about 1 hour to complete for the
individual data for butadiene, and about 4.5 hours for the aggregated data using Model
19
III. While these times are not long, more complicated models and data could substantially
increase the computation time and the chain length necessary for convergence. These prac-
tical limitations could be alleviated by either more efficient MCMC algorithms or faster
computing power than we have used here.
Ideally, of course, individual data would always be available for analysis, and it is sound
practice to use all such data. It should not be inferred from our analysis that summary data
should be used when individual data are available, as data aggregation always entails a degree
of information loss. However, especially in a toxicological/environmental health setting where
data are often gathered from multiple, usually historical, sources, the original data may be
unavailable. The effort, then, should be to maximize the use of the available information,
particular in the case of human data where unnecessary exposure to toxicants should be
minimized. Typically, no attempt is made to extract population variability information from
aggregated data, perhaps because it is presumed to be unimportant or to have been lost in the
aggregation process. Our analysis shows this information is not necessarily completely lost
— that when both the mean and variance are reported, significant information on population
variability may remain. We have presented here an example of application to the analysis
of toxicokinetic data, but aggregation of data for publication has been pervasive in biology,
and occasions to test the approach we propose should be plentiful. For example, in cancer
bioassays, groups of animals are exposed to predetermined doses of a carcinogen and the onset
of tumors is observed. Each animal is expected to react differently to the exposure. Such
inter-individual variability can be studied if time-to-event reporting of tumors is available.
However, most of the time (e.g. the carcinogenic potency database of Lois Gold at Berkeley,
Gold, Manley, Slone, and Rohrbach 1999) only the number of animals bearing tumors at
the end of the experiment is kept and analyzed with binomial or Poisson regressions. A
better understanding of the variabilities and uncertainties involved in such experiments would
probably benefit society as a whole.
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Table 1: Approximate Likelihood Functions for Aggregated Data
Error Model Approximate Likelihood Function
I: yi ∼ N(fi, σ) (m, s2) ∼ N(µm, σm, µs2 , σs2 , r)




2]− E[f ]2 + (n− 1)σ2m
σ2s2 = 4σ
2
m {µs2 − (n− 1)σ2m/2}
r = 0
II: yi ∼ N(fi, fiσ) (m, s2) ∼ N(µm, σm, µs2 , σs2 , r)




2]− E[f ]2 + (n− 1)σ2m
σ2s2 = 4σ
2 (E[f4]− 2E[f3]E[f ] + E[f2]E[f ]2) /n
+2σ4 {(n− 2)E[f 4] + E[f2]2} /n2








III: ln yi ∼ N(ln fi, σ) (lnm, lnm2) ∼ N(µm, σm, µm2 , σm2 , r)
µm = ln E[f ] + (σ
2 − σ2m)/2
σ2m = ln{1 + (expσ2 − 1)E[f 2]/(E[f ]2n)}
µm2 = ln E[f
2] + (4σ2 − σ2m2)/2












Note: fi ≡ f(θi) and E[f q] ≡ ∑ni=1 f qi /n
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Table 2: Comparison of Individual and Aggregated Analyses of Simulated Data. The model
is f1 = exp(−κ1t) and f2 = (1 − f1) exp(−κ2t), with the population distributions of κ1,2
given by lnκ1,2 ∼ N(µ1,2,Σ1,2), and measurement error models y1,2 ∼ N(f1,2, σ1,2), y1,2 ∼
N(f1,2, f1,2σ1,2), ln y1,2 ∼ N(ln f1,2, σ1,2), for error models I, II, and III, respectively. Prior
distributions are µ1,2 ∼ N(0, 2), Σ21,2 ∼∼ InvΓ(1, 0.01), and σ21,2 ∼∼ InvΓ(1, 0.01). Posterior
values are median97.5%2.5% , based on 5 chains, each of length 11,000, with the last 7000 for
inference. Simulated data is cross-sectional, with 8 individuals at each of N = 6 time points.
Similar results (not shown) are obtained from longitudinal data (N = 6, n = 8).
Error Parameter
Model Analysis µ1 exp Σ1 expσ1 µ2 exp Σ2 expσ2
All True Value: 0.50 1.28 1.064 −0.50 1.13 1.064
All Sample Value: 0.49 1.26 1.068 −0.52 1.13 1.064









1.042 −0.53−0.49−0.56 1.111.151.08 1.0711.1271.044









1.043 −0.53−0.49−0.57 1.111.161.08 1.0691.1211.043































Figure 1: Graphical representation of population statistical model describing dependence
relationships between variables. Square nodes are known or measured quantities, circle nodes
are unknown or unobserved, solid arrows indicate a stochastic dependence, and dashed arrows
indicate a logical (functional) dependence. The inverted triangle f represents the nonlinear
pharmacokinetic model prediction. Individuals are labeled by the index i. It should be
noted that all of the nodes may have additional dimensions in addition to i (e.g., multiple
time points, tissues). The left model represents the situation where individual data yi are
available. Aggregation of data leads to the middle model, where only m, s2, and n are
available (note yi is still part of the model, but has changed from a square node, denoting
a measured quantity, to a circle node, indicating an unobserved quantity). Marginalization
over yi leads to the model on the right, which is used in our analyses. Approximations for
the results of this marginalization for various measurement models are described in the text.
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Table 3: Comparison of Individual and Aggregated Analyses of 1,3-Butadiene Data. Each
pharmacokinetic model parameter has an associated population mean µ and variance Σ2.
Individual analyses used error model III (Bois et al. 1999). Aggregated analyses for error
model I used log-transformed measurements; those for error models II and III used un-
transformed measurements. Prior distributions on µ and Σ2 are specified below, as are the
posterior median97.5%2.5% on µ and exp Σ based on two independent chains of 50,000 iterations,
thinned by 10, with the first 10,000 iterations discarded. For the prediction AMET, GM8 and
GSD8 are the geometric mean and geometric standard deviation of 8 individuals, respectively.
Parameter or Priors (µ, Σ2) Posteriors (µ, exp Σ) from Analyses:
Prediction Individual Model I Model II Model III







































































































































































































Figure 2: Exhaled breath concentration data used in 1,3-butadiene analysis. Individual
data are shown in the points. Aggregated data are shown in the left panel (square, with
one-standard deviation error bars), but only at data points where all 8 subjects had mea-
surements. The solid bar indicates the time during which exposure (at 5 ppm) occurred.
The middle and right panels show comparison of the original individual data with posterior
simulations (without “measurement” error) for the samples with the highest posterior like-
lihood (solid lines) for analysis of individual data (center panel) and aggregated data using















































sc_Vc Kcp PpcVp Kmet Pca sc_Kin BDW GSD
Figure 3: Median (symbols) and [2.5%,97.5%] confidence interval (error bars) for prior (open
circle) and posterior (solid symbols) distributions for the population means (upper panel)
and inter-/intra-individual variances (lower panel). Solid symbols represent full population
analysis of individual data (square), and aggregated analyses for Models I-III (solid circle,
triangle, and diamond, respectively).
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